She was told it was impossible.
For 30 years nobody funded her research. Nobody believed in what she was studying. She was a Brazilian biologist working alone on a question that the medical world had already given up on.
What if the spinal cord could heal itself?
Her name is Dr. Tatiana Coelho de Sampaio.
And she never stopped asking.
She discovered a protein called laminin. The same substance that guides our neurons as we grow in the womb. She figured out how to polymerize it. How to make it more powerful. How to inject it into a broken spinal cord and give damaged neurons a road to grow back on.
Paralyzed rats walked again.
Dogs with chronic spinal cord injuries regained movement.
Then came the human study.
Eight patients. Complete spinal cord injuries. A single injection within 72 hours of trauma.
Every single survivor regained voluntary motor control below the level of their lesion.
Every. Single. One.
I have spent decades in the operating room. I have sat with patients and families after the kind of injuries that change everything in an instant. I know what it feels like to deliver news that leaves no room for hope.
This leaves room for hope.
It is still experimental. Clinical trials are just beginning. Dr. Sampaio herself calls it a promise. Not yet a proven cure.
But this is how medicine changes forever.
Does polylaminin work?
Polymerized laminin promoted axonal regeneration and functional recovery in rats and dogs. Eight people treated with laminin demonstrated voluntary motor contraction. Brazil has authorized a phase 1 human study.Feb 26, 2026
Regeneration of spinal cord injury (SCI) is a major topic of biomedical research. Laminin is an extracellular matrix protein implicated in neural development and regeneration, but despite that, there are no reports of exogenous laminin contributing to improve the outcome of experimental SCI. Here we investigated whether a biomimetic polymer of laminin assembled on pH acidification, henceforth called polylaminin, could be used to treat SCI in rats. Acute local injection of polylaminin, but not of nonpolymerized laminin, improved motor function after thoracic compression, partial or complete transection. In the latter case, the BBB score for open field locomotion 8 wk after lesion increased from 4.2 ± 0.48 to 8.8 ± 1.14 in animals treated with polylaminin of human origin. Accordingly, neurons retrogradely labeled from the sublesion stump were detected in the spinal cord and brain stem, indicating regrowth of short and long fibers across a complete transection. Polylaminin also played an unsuspected anti-inflammatory role, which underlies the early onset of its positive effects on locomotion from the first week after treatment. The beneficial effects of polylaminin were not observed in animals treated with the nonpolymerized protein or vehicle only. We propose that polylaminin is a promising therapeutic agent to treat human SCI.
One person. One question. Thirty years of not giving up.
Save this. Share it with someone who needs to believe that what was broken can be rebuilt.
No comments:
Post a Comment